Microbix Biosystems (MBX) Competitors C$0.23 -0.01 (-2.13%) As of 08/22/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock MBX vs. ONC, SCYB, COM, NVH, IGX, MDNA, HBP, PDP, COV, and APSShould you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Helix BioPharma (HBP), Pediapharm (PDP), Covalon Technologies (COV), and Aptose Biosciences (APS). These companies are all part of the "biotechnology" industry. Microbix Biosystems vs. Its Competitors Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Medicenna Therapeutics Helix BioPharma Pediapharm Covalon Technologies Aptose Biosciences Oncolytics Biotech (TSE:ONC) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Which has higher valuation & earnings, ONC or MBX? Microbix Biosystems has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-C$27.66M-C$0.36-3.96Microbix BiosystemsC$24.42M1.24C$3.39MC$0.038.76 Do analysts recommend ONC or MBX? Oncolytics Biotech presently has a consensus target price of C$3.50, suggesting a potential upside of 146.48%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Oncolytics Biotech is more favorable than Microbix Biosystems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Microbix Biosystems 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ONC or MBX more profitable? Microbix Biosystems has a net margin of 13.86% compared to Oncolytics Biotech's net margin of 0.00%. Microbix Biosystems' return on equity of 12.65% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.94% -71.33% Microbix Biosystems 13.86%12.65%3.82% Do insiders & institutionals have more ownership in ONC or MBX? 1.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 0.4% of Microbix Biosystems shares are held by institutional investors. 3.8% of Oncolytics Biotech shares are held by company insiders. Comparatively, 14.0% of Microbix Biosystems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor ONC or MBX? In the previous week, Oncolytics Biotech's average media sentiment score of 0.39 beat Microbix Biosystems' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Overall Sentiment Oncolytics Biotech Neutral Microbix Biosystems Neutral Which has more volatility and risk, ONC or MBX? Oncolytics Biotech has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Microbix Biosystems has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. SummaryMicrobix Biosystems beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks. Get Microbix Biosystems News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMicrobix BiosystemsBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$30.29MC$137.16MC$5.75BC$6.37BDividend Yield2.30%3.74%4.40%6.72%P/E Ratio8.763.8731.3673.11Price / Sales1.244,057.33434.711,702.26Price / Cash4.1313.1937.7383.29Price / Book1.1146.309.534.91Net IncomeC$3.39M-C$90.99MC$3.26BC$301.20M7 Day Performance-6.12%0.61%2.12%1.35%1 Month Performance-22.03%3.70%2.80%1.88%1 Year Performance-35.21%205.89%30.68%27.39% Microbix Biosystems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMicrobix BiosystemsN/AC$0.23-2.1%N/A-36.1%C$30.29MC$24.42M8.76N/AONCOncolytics Biotech1.6556 of 5 starsC$1.36-2.9%C$3.50+157.4%+9.2%C$104.82MN/A-3.7929Gap DownSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap UpMDNAMedicenna TherapeuticsN/AC$1.07-1.8%N/A-47.9%C$80.05MC$4.87K-2.9520HBPHelix BioPharmaN/AC$1.35-2.2%N/A+17.4%C$71.58MN/A-1.429News CoverageGap DownPDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/ACOVCovalon TechnologiesN/AC$2.42-16.0%N/A-23.8%C$66.30MC$27.87M27.78N/ANews CoveragePositive NewsGap DownAPSAptose BiosciencesN/AC$1.53-11.6%N/A-90.4%C$65.88MN/A-0.3031News Coverage Related Companies and Tools Related Companies Oncolytics Biotech Competitors Scythian Biosciences Competitors 138267 (COM.TO) Competitors Novoheart Competitors IntelGenx Technologies Competitors Medicenna Therapeutics Competitors Helix BioPharma Competitors Pediapharm Competitors Covalon Technologies Competitors Aptose Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:MBX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Microbix Biosystems Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Microbix Biosystems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access